Business Wire

Eaton’s Vehicle Group Secures U.S. Department of Energy Grant to Develop Emissions-reducing Technologies for the Agricultural Sector

Share

Power management company Eaton today announced its Vehicle Group has secured a $2.4 million grant from the U.S. Department of Energy (DOE) to develop new technologies to reduce emissions from agricultural equipment. This grant will accelerate Eaton’s progress in achieving its 2030 Sustainability Targets. By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005939/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s variable valve actuation technologies are an ideal solution for reducing emissions produced by agricultural implements. (Photo: Business Wire)

Under the grant, Eaton plans to develop technologies that simultaneously reduce greenhouse gas (GHG) by 10% and nitrogen oxides (NOx) by 90% for agricultural powertrains designed for multiple-duty cycles. The technologies are required to span application diversity in the segment while being both cost-efficient and robust. Separately, Eaton also received a $4.9 million grant to develop a new compact and modular solid-state transformer to reduce the cost and size of DC fast-charging systems.

“Off-highway sector emissions levels, including in the agricultural segment, significantly lag behind on-road applications due to a lack of technology solutions,” said Dr. Mihai Dorobantu, director, Technology Planning and Government Affairs, Eaton’s Vehicle Group. “This grant could enable significant reductions in both GHG and NOx emissions that would then drive the technology and its benefits nationwide and help us meet our corporate sustainability objectives. The DOE funding supports our ongoing work to develop technologies that reduce emissions in applications that are difficult to decarbonize. The funding also enables research partnerships to optimize architectures and components.”

To achieve the grant’s objective, Eaton’s Vehicle Group will develop new components for agricultural applications and will modify existing technologies developed for commercial vehicles, including engine and aftertreatment systems. Agricultural solutions differ from advanced on-road technologies because they are used in unique and varying operating cycles.

An expansive portfolio of technologies will be leveraged to achieve target goals

By partnering with leading engine manufacturers, Eaton plans to achieve the DOE targets through innovative technologies that provide higher engine compression ratios, reduce friction and increase turbo machinery efficiency while minimizing mechanical losses.

Eaton will adapt its line of variable-valve actuation (VVA) solutions, originally designed for commercial vehicles, for agricultural use. Eaton’s VVA technologies are based on two building blocks — a rocker with a switchable capsule, and a split rocker for full deactivation. By combining these two building blocks, several VVA strategies can be utilized in virtually any engine architecture — from single and dual overhead cam to cam-in-designs, for engine displacements ranging from 2.0 to 15.0 liters.

Cylinder deactivation (CDA) is a VVA technology that consists of deactivating the intake and exhaust valve opening, as well as the fuel injection on some of the cylinders when the engine is running at low load. CDA is an ideal solution for commercial vehicles that make frequent stops, as well as many agricultural implements. CDA can reduce NOx emissions by up to 40% and carbon dioxide (CO2) by 5%-8%.

Eaton will also focus on active catalyst heating technology to assist with exhaust thermal management as part of achieving the DOE’s targets. Active heating solutions provide heat directly to the vehicle’s aftertreatment system, reducing harmful NOx emissions by warming the selective catalytic reduction (SCR) catalyst to approximately 200-250 degrees Celsius as quickly as possible, and maintaining this temperature during periods of low-load operation.

Additionally, Eaton plans to leverage its positive-displacement TVS® exhaust gas recirculation (EGR) pump to meet the program’s objectives. The EGR pump complements a high-efficiency turbocharger to reduce engine pumping losses, thereby increasing fuel economy and lowering emissions. Because the pump is a positive-displacement device, the engine controller uses the pump speed signal, as well as other Controller Area Network (CAN) sensor data, to accurately calculate EGR mass flow rate.

“This program is foundational to creating two market drivers in the off-highway segment —upcoming regulations to lower GHG and NOx emissions across the segment, and a significant economic benefit generated for end users,” Dorobantu said.

The DOE DC fast-charging grant aims to significantly reduce the time it takes to install charging infrastructures at end-user facilities. Eaton’s new technology will feature advanced components and an innovative cooling approach, eliminating the need for multiple power conversion devices. The goal is to reduce charging infrastructure barriers to commercial electric vehicle deployment by minimizing the need for facility modifications and allowing for charging installations in remote areas. The grant aligns with the DOE’s commitment to have zero-emission vehicles make up half of all vehicles sold in America by 2030 and achieve net-zero emissions economywide by 2050.

The grant also supports Eaton’s Vehicle Group and eMobility business's mission to produce sustainable solutions that enhance vehicle efficiency, safety and performance. Our Vehicle products include emission control components, engine valves, valvetrain systems, superchargers, transmissions, clutches and torque management systems. Our eMobility portfolio includes intelligent power electronics, reliable power distribution and protection solutions, and efficient power systems for electrified vehicles.

Learn more about Eaton’s Vehicle Group and eMobility businesses.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release

Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release

Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i

Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye